Literature DB >> 32862333

New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature.

Lula María Nieto-Benito1, Ofelia Baniandrés-Rodríguez2.   

Abstract

Entities:  

Year:  2020        PMID： 32862333     DOI： 10.1007/s40261-020-00964-w

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  10 in total

Review 1.  Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature.

Authors:  M Munera-Campos; F Ballesca; J M Carrascosa
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2018-06-11

Review 2.  Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.

Authors:  Éric Toussirot; François Aubin
Journal:  RMD Open       Date:  2016-07-15

3.  Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study.

Authors:  Jung Min Bae; Miri Kim; Han Hee Lee; Ki-Jo Kim; Hyoseung Shin; Hyun Jeong Ju; Gyong Moon Kim; Chul Jong Park; Hyun Jeong Park
Journal:  J Invest Dermatol       Date:  2017-11-23       Impact factor: 8.551

Review 4.  Why treatments do(n't) work in vitiligo: An autoinflammatory perspective.

Authors:  Reinhart Speeckaert; Marijn M Speeckaert; Nanja van Geel
Journal:  Autoimmun Rev       Date:  2014-12-12       Impact factor: 9.754

5.  Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea.

Authors:  Jung Min Bae; June Hyunkyung Lee; Jae Seung Yun; Byeol Han; Tae Young Han
Journal:  J Am Acad Dermatol       Date:  2017-02-24       Impact factor: 11.527

6.  IL-17A is not a treatment target in progressive vitiligo.

Authors:  Reinhart Speeckaert; Sofie Mylle; Nanja van Geel
Journal:  Pigment Cell Melanoma Res       Date:  2019-05-21       Impact factor: 4.693

7.  New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases.

Authors:  L Méry-Bossard; K Bagny; G Chaby; A Khemis; F Maccari; H Marotte; J L Perrot; Z Reguiai; M L Sigal; M Avenel-Audran; T Boyé; A Grasland; J Gillard; D Jullien; E Toussirot
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-13       Impact factor: 6.166

8.  Interleukin-17 level in patients with vitiligo: A systematic review and meta-analysis.

Authors:  Prakash Acharya; Mahesh Mathur
Journal:  Australas J Dermatol       Date:  2020-01-02       Impact factor: 2.875

9.  Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?

Authors:  Joon Min Jung; Ye Jin Lee; Chong Hyun Won; Sung Eun Chang; Mi Woo Lee; Jee Ho Choi; Kee Chan Moon
Journal:  Ann Dermatol       Date:  2015-10-02       Impact factor: 1.444

Review 10.  Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon.

Authors:  Alessio Mylonas; Curdin Conrad
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561
  10 in total
  2 in total

Review 1.  Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.

Authors:  Paolo Custurone; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Domenica Altavilla; Alessandra Bitto; Giovanni Pallio; Francesco Squadrito; Mario Vaccaro
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

2.  Onset of vitiligo in a psoriasis patient on ixekizumab.

Authors:  Claudio Marasca; Luigi Fornaro; Fabrizio Martora; Vincenzo Picone; Gabriella Fabbrocini; Matteo Megna
Journal:  Dermatol Ther       Date:  2021-09-02       Impact factor: 3.858
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.